Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seagen Inc.
Genmab
M.D. Anderson Cancer Center
Eastern Cooperative Oncology Group
Bayer
Yonsei University
Washington University School of Medicine
University of California, Davis
City of Hope Medical Center
University of California, San Diego
UNC Lineberger Comprehensive Cancer Center
Emory University
ImmunityBio, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Novartis
Washington University School of Medicine
University of Cincinnati
Inhibrx Biosciences, Inc
Universität des Saarlandes
Roswell Park Cancer Institute
Nanobiotix
Washington University School of Medicine
National Institutes of Health Clinical Center (CC)
University of Chicago
University of Pittsburgh
Asher Biotherapeutics, Inc.
Exelixis
ALX Oncology Inc.
ALX Oncology Inc.
Rakuten Medical, Inc.
University of Cincinnati
Compugen Ltd
The Methodist Hospital Research Institute
Latin American Cooperative Oncology Group
National Cancer Institute (NCI)
Salubris Biotherapeutics Inc
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
R-Pharm